Many signaling pathways are found to be involved in the pathogeny of NKTCL, among which, NF‐κB and JAK/STAT are the best studied.26, 27 Studies showed that NF‐κB mutation was related to drug resistance among NKTCL patients.28 From 65 cases of NKTCL patients, Koo et al29 found 23 cases (35.4%) showed JAK3 mutation, indicating that JAK/STAT signaling pathway is involved in the oncogenesis and progression of NKTCL. The gene discussed is NFKB1; the disease is extranodal nasal NK/T cell lymphoma.